We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Internet-based Metacognitive Therapy for Excessive Worry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03393156
Recruitment Status : Recruiting
First Posted : January 8, 2018
Last Update Posted : January 8, 2018
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to examine if an internet-based metacognitive therapy reduces negative metacognitions and if reductions negative metacognitions mediates reductions in worry.

Condition or disease Intervention/treatment
Excessive Worry Behavioral: Internet-based metacognitive therapy

Detailed Description:

Our main aim is to investigate if an internet-based metacognitive intervention (I-MCT) can reduce negative metacognitions in a sample of high worriers. Clear change in negative metacognitions in one group relative to another is required to test the mechanistic hypothesis. We are not investigating the intervention elements that might lead to change. Our primary aim is to investigate whether I-MCT for worry, compared with waiting list, reduces negative metacognitions and reduced worry by the end of treatment, and whether the changes in negative metacognitions mediates the changes in worry. Our hypotheses are the following: 1) I-MCT reduces negative metacognitions and worry from baseline to week 10, 2) reductions in negative metacognitions will significantly mediate subsequent reductions in worry. Additionally we hypothesize that patients who score low at baseline in negative metacognitions will not show this pattern i.e. 3) patients who score low at baseline in negative metacognitions will benefit less from treatment and consequently 4) will not show the same mediation response as in hypothesis 2.

Trial Design: Randomized controlled trial with waitlist control. Duration: Ten weeks Primary Endpoint: Change in worry symptoms and negative metacognitions from baseline to Week 10. Long term follow-up is also investigated (baseline to 6-months after treatment completion and baseline to 12-months after treatment completion).

Efficacy Parameters: Penn State Worry Questionnaire (PSWQ) and the negative metacognitions subscale of the Meta-Cognitions Questionnaire 30 items.

Safety Parameters: Adverse Events is assessed at week 10. Description of Trial Subjects: Patients > 18 years old with a PSWQ score more than 56 points Number of Subjects: Anticipated 140


Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Internet-based Metacognitive Therapy for Excessive Worry: A Randomized Controlled Trial
Anticipated Study Start Date : January 10, 2018
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : May 2018
Arms and Interventions

Arm Intervention/treatment
Experimental: Internet-based metracognitive therapy
The internet-based metacognitive therapy group receives a ten-week long treatment, which is based on the book "Metacognitive therapy for depression and anxiety" by Adrian Wells (2011).
Behavioral: Internet-based metacognitive therapy
Internet-based metacognitive therapy on a safe internet platform. Treatment is divided into ten modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hour
No Intervention: Wait-list
When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, 6 and 12 months later using the same questionnaires as the treatment group.


Outcome Measures

Primary Outcome Measures :
  1. Penn State Worry Questionnaire (PSWQ) [ Time Frame: Weekly measurements week 0-10, 6 and 12 months follow-up ]
    Change in worry, weekly measurements, and at 6 and 12 months after treatment has ended.

  2. Negative beliefs about uncontrollability of thoughts and danger in the Meta Cognitions Questionnaire (MCQ-30) [ Time Frame: Weekly measurements week 0-10, 6 and 12 months follow-up ]
    Change in Negative beliefs about uncontrollability of thoughts and danger, weekly measurements, and at 6 and 12 months after treatment has ended.


Secondary Outcome Measures :
  1. Montgomery Åsberg Depression Rating Scale (MADRS-S) [ Time Frame: Week 0, Week 10, 6 and 12 months follow-up ]
    Change in depression from baseline to Week 10 and at 6 and 12 months after treatment has ended.

  2. Euroqol, EQ-5D [ Time Frame: Week 0, Week 10, 6 and 12 months follow-up ]
    Change in general health from baseline to Week 10 and at 6 and 12 months after treatment has ended

  3. Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry (TIC-P) [Time Frame: Week 0, Week 10, 4 and 12 months follow-up] [ Time Frame: Week 0, Week 10, 6 and 12 months follow-up ]
    Change in economic costs from baseline to Week 10 and at 6 and 12 months after treatment has ended

  4. Meta Cognitions Questionnaire (MCQ-30) [ Time Frame: Weekly measurements, 6 and 12 months follow-up ]
    Change in metacognitions (all subscales as a total sum) weekly and at 6- and 12 months after treatment has ended.

  5. Cognitive Avoidance Questionnaire (CAQ) [ Time Frame: Week 0, Week 10, 6 and 12 months follow-up ]
    Change in cognitive avoidance from baseline to Week 10 and at 4- and 12 months after treatment has ended

  6. Adverse Events [ Time Frame: Week 0, Week 10, 6 and 12 months follow-up ]
    Number of adverse events from baseline to Week 10 and at 6 and 12 months


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Outpatients
  • ≥ 18 years
  • Situated in Sweden
  • Informed consent
  • PSWQ score more than 56 points

Exclusion Criteria:

  • Substance dependence during the last six months
  • Post traumatic stress disorder, bipolar disorder or psychosis
  • Symptoms better explained by axis 2 diagnosis (e.g. autism or borderline personality disorder)
  • MADRS-S score above 25 points
  • Psychotropic medication changes within two months prior to treatment that could affect target symptoms.
  • Received metacognitive therapy for pathological worry the last 2 years.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03393156


Contacts
Contact: Erik M Andersson, PhD, Psych. 08 - 524 824 46 erik.m.andersson@ki.se
Contact: Tove Wahlund, Psych. tove.wahlund@ki.se

Locations
Sweden
Karolinska Intitutet Recruiting
Stockholm, Sweden, 17177
Contact: Erik M Andersson, PhD, Psych.    08 - 524 824 46    erik.m.andersson@ki.se   
Sponsors and Collaborators
Karolinska Institutet
Investigators
Principal Investigator: Erik M Andersson, PhD, Psych. Karolinska Institutet
More Information

Responsible Party: Erik Andersson, PhD, Lic. psychologist, Karolinska Institutet
ClinicalTrials.gov Identifier: NCT03393156     History of Changes
Other Study ID Numbers: 2017/1998-31
First Posted: January 8, 2018    Key Record Dates
Last Update Posted: January 8, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No